• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
KAN Min,WU Yuanyuan,SHAO Hua.Application and research progress of Amphotericin B for the treatment of mucormycosis[J].Journal Of Pharmaceutical Research,2026,45(1):82-89[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2808times   Download 813次 QR Code for this article
Scan with your phone!
两性霉素B在毛霉病治疗中的应用与研究进展
阚敏,吴园园,邵华
Font:Larger+|Default|Smaller-
(东南大学附属中大医院药学部,江苏 南京 210009)
摘要:
毛霉病是一种致死率高的侵袭性真菌感染,两性霉素B(AmB)作为核心治疗药物,对毛霉菌具有显著的体外抗菌活性,其单药治疗的疗效与安全性已获多项临床试验和回顾性研究证实。有研究提示AmB与唑类、棘白菌素类药物存在协同抗菌作用,以及局部联合静脉给药可优化疗效,但均为病例报告或小样本回顾性研究,尚缺乏高级别循证支持。本文综述了毛霉病的流行病学特征、AmB体外抗菌活性及其临床应用进展,以期为优化AmB治疗策略提供思路及方向。
关键词:  两性霉素B  毛霉病  侵袭性真菌感染
DOI:10.13506/j.cnki.jpr.2026.01.012
基金项目:江苏省药学会-奥赛康医院药学基金科研项目(No.A202105);南京药学会-常州四药医院药学科研基金(No.2021YX008)
Publication Date:January 26, 2026
Application and research progress of Amphotericin B for the treatment of mucormycosis
KAN Min,WU Yuanyuan,SHAO Hua
(Department of Pharmacy,Zhongda Hospital, Southeast University, Nanjing 210009, China)
Abstract:
Mucormycosis is an invasive fungal infection with high mortality. Amphotericin B (AmB), as the cornerstone therapeutic drug, demonstrates potent in vitro antifungal activity against Mucorales. The efficacy and safety as monotherapy have been confirmed by multiple clinical trials and retrospective studies. Emerging studies suggest potential synergistic effects between AmB and azoles or echinocandins, as well as enhanced therapeutic outcomes through combined local and intravenous administration. However, these findings are currently limited to case reports or small-scale retrospective studies, lacking high-level evidence-based support. This article reviews the epidemiological characteristics of mucormycosis, the in vitro antifungal activity of AmB, and the progress of its clinical applications, aiming to provide insights and future directions for optimizing AmB-based treatment strategies.
Key words:  Amphotericin B  Mucormycosis  Invasive fungal infection
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.